Stockreport

Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

Achieve Life Sciences, Inc. - Common Shares  (ACHV) 
Last achieve life sciences, inc. - common shares earnings: 3/13 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.achievelifesciences.com
PDF Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo   Cytisinicline treatment well tolerated [Read more]